The role of platelets and platelet-derived microvesicles in diabetic nephropathy.

The role of platelets and platelet-derived microvesicles in diabetic nephropathy. - PlaDNer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47280

Enrollment

144

Registered

2018-11-22

Start date

2018-10-09

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic kidney injury Diabetic nephropathy

Interventions

diabetic nephropathy

microvesicles

miRNA

Platelets

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Type 2 diabetes Age between 18-70 year

Exclusion criteria

Exclusion criteria: Smoker User of anti-platelet drugs South-Asian or Sub-Sahara ethnicity

Design outcomes

Primary

Measure	Time frame
The main parameter of this study is the content of mRNA and miRNA in platelets and PMVs.	—

Secondary

Measure	Time frame
Plasma and urinary microvesicles and inflammatory markers (e.g. TNF-alpha, il-6, il-8, il-1*), renal injury markers (e.g. Cystatin-C, nGAL), as well as platelet activity markers (platelet factor 4 and serotonin) and agonist-induced platelet aggregation (platelet count-based test) are secondary study parameters.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)